Shares of Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) have received a consensus rating of “Hold” from the four research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $6.00.
Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Rein Therapeutics in a research report on Tuesday. Maxim Group assumed coverage on shares of Rein Therapeutics in a research report on Monday, July 20th. They set a “buy” rating and a $4.00 target price on the stock. Weiss Ratings upgraded shares of Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th.
Rein Therapeutics News Roundup
- Positive Sentiment: The U.S. FDA granted Fast Track designation to LTI-03 for idiopathic pulmonary fibrosis (IPF). The designation recognizes the serious unmet need in IPF and could facilitate development, regulatory interactions, and review of the therapy. Rein said the Phase 2 RENEW trial is actively enrolling and remains on track to report interim data in the second half of 2026. Fast Track is not an approval, so upcoming clinical data remain the key catalyst. Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
- Positive Sentiment: HC Wainwright reiterated its Buy rating, while a separate report cited a $6.00 price target—well above recent trading levels. These views may provide valuation support, although analyst targets are forecasts rather than guarantees. HC Wainwright Reiterates Buy Rating for Rein Therapeutics Analysts Set Rein Therapeutics Price Target at $6.00
- Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.47 from a loss of $0.53, suggesting somewhat better near-term expectations and matching the broader annual forecast cited for the company.
- Neutral Sentiment: The same analyst modestly lowered projected losses for FY2028, FY2029, and fourth-quarter 2026, indicating that longer-term profitability expectations remain uncertain despite the continued Buy rating. The changes were small, with estimates still calling for losses through FY2029.
- Neutral Sentiment: Overall, the FDA milestone is the strongest near-term development for RNTX, while interim RENEW data expected in the second half of 2026 may determine whether the recent regulatory momentum translates into a sustained stock-price increase.
Rein Therapeutics Stock Performance
NASDAQ RNTX opened at $0.79 on Friday. Rein Therapeutics has a twelve month low of $0.69 and a twelve month high of $2.18. The stock has a market capitalization of $68.46 million, a PE ratio of -0.46 and a beta of 1.39. The stock has a 50-day simple moving average of $0.88 and a 200 day simple moving average of $1.12.
Rein Therapeutics (NASDAQ:RNTX – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. As a group, equities research analysts forecast that Rein Therapeutics will post -0.47 EPS for the current fiscal year.
Institutional Investors Weigh In On Rein Therapeutics
Several hedge funds have recently made changes to their positions in RNTX. Susquehanna International Group LLP acquired a new stake in Rein Therapeutics during the third quarter worth about $35,000. HRT Financial LP acquired a new position in Rein Therapeutics in the 4th quarter valued at approximately $38,000. Chicago Partners Investment Group LLC lifted its position in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Rein Therapeutics in the 2nd quarter worth approximately $68,000. Finally, Jane Street Group LLC acquired a new stake in shares of Rein Therapeutics during the 4th quarter worth approximately $72,000. Institutional investors own 90.89% of the company’s stock.
Rein Therapeutics Company Profile
Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.
The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Rein Therapeutics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
